A study published in the British Journal of Cancer found that co-mutations in the KRAS and TP53 genes predict a better response to immune checkpoint inhibitors (ICIs) in lung adenocarcinoma patients. The research analyzed 713 patients with advanced lung adenocarcinoma who did not have actionable genetic alterations, along with two external cohorts. The study showed that patients with KRAS and TP53 co-mutations had significantly better survival rates compared to those without such mutations. This benefit was observed in immunotherapy cohorts but not in surgical ones. Tumors with TP53 mutations had higher mutational burden, proliferation, and PD-L1 mRNA levels. Genome-wide expression analysis identified 64 genes, including CX3CL1, as specific to KRASmut/TP53mut tumors. The study concludes that KRAS/TP53 co-mutation is a predictive biomarker for ICI benefit and is associated with unique molecular features. Mutation testing for these genes can be easily implemented using small NGS panels. The findings suggest that KRAS/TP53 co-mutation could be a valuable biomarker for identifying patients who may benefit from ICI therapy.A study published in the British Journal of Cancer found that co-mutations in the KRAS and TP53 genes predict a better response to immune checkpoint inhibitors (ICIs) in lung adenocarcinoma patients. The research analyzed 713 patients with advanced lung adenocarcinoma who did not have actionable genetic alterations, along with two external cohorts. The study showed that patients with KRAS and TP53 co-mutations had significantly better survival rates compared to those without such mutations. This benefit was observed in immunotherapy cohorts but not in surgical ones. Tumors with TP53 mutations had higher mutational burden, proliferation, and PD-L1 mRNA levels. Genome-wide expression analysis identified 64 genes, including CX3CL1, as specific to KRASmut/TP53mut tumors. The study concludes that KRAS/TP53 co-mutation is a predictive biomarker for ICI benefit and is associated with unique molecular features. Mutation testing for these genes can be easily implemented using small NGS panels. The findings suggest that KRAS/TP53 co-mutation could be a valuable biomarker for identifying patients who may benefit from ICI therapy.